Heart:严重三尖瓣反流伴充血性心衰患者的预后分析

2019-11-18 不详 网络

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。

本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的随访,那些接受了手术治疗的患者生存率明显高于接受药物治疗的患者(62% vs 35%; p<0.001)。多变量分析后发现,年龄、中重度右室功能不全与更高的死亡率相关,TVS与更低的死亡率呈相关性(HR: 0.44; 95% CI 0.27-0.71)。

研究结果显示,对于严重三尖瓣反流伴充血性心衰患者,三尖瓣手术可以明显降低死亡率,但仍有部分患者接受了药物治疗。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2019-11-20 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2019-11-20 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2019-11-20 feifers
  7. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2019-11-19 thm112988

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2046322, encodeId=a2ee204632257, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Oct 25 04:24:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357301, encodeId=aef3135e3016d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373459, encodeId=a3f613e34599d, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407838, encodeId=13de140e838f2, content=<a href='/topic/show?id=f73019633bf' target=_blank style='color:#2F92EE;'>#三尖瓣反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19633, encryptionId=f73019633bf, topicName=三尖瓣反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec6c2728397, createdName=meichuangyi, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563171, encodeId=2ba115631e1d1, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571669, encodeId=e50815e166905, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578475, encodeId=bfad15e8475a4, content=<a href='/topic/show?id=a1021962883' target=_blank style='color:#2F92EE;'>#三尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19628, encryptionId=a1021962883, topicName=三尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb16409801, createdName=124985dbm11(暂无昵称), createdTime=Wed Nov 20 01:24:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375520, encodeId=24f93e55204b, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Nov 19 06:28:46 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375510, encodeId=bbb43e551010, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Nov 18 20:45:19 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2019-11-18 天地飞扬

    学习

    0

相关资讯

JACC:造影前做心脏磁共振是诊断心梗的新策略

非ST段抬高型心梗伴高敏肌钙蛋白水平升高的患者常规会接受有创的冠脉造影(ICA)检查,但经常会没有冠脉梗阻。本研究的目的旨在评估心脏磁共振(CMR)和计算机断层血管造影(CTA)是否可能成为ICA前的筛选手段。本次随机对照临床试验纳入分析了207名急性胸痛、高敏肌钙蛋白T升高(>14 ng/l)且超声心动图没有确诊的患者(平均年龄64岁,男性占62%)。当初始的CMR或CTA提示为心肌缺血、

JACC:伊伏洛单抗可明显降低急性冠脉综合征患者早期胆固醇水平

尽管指南推荐急性冠脉综合征(ACS)患者应在住院期间启动高强度他汀类药物治疗,但低密度脂蛋白胆固醇(LDL-C)的目标水平经常达不到。本研究的目的旨在伊伏洛单抗(evolocumab)在ACS患者急性住院期间的降脂效果和可行性。本次随机双盲对照试验纳入分析了308例LDL-C水平增高的ACS住院患者,患者随机分成皮下注射伊伏洛单抗组或安慰剂组。主要终点事件是基线到8周LDL-C水平的变化百分比。大

JACC:影响轻中度主动脉反流患者的自然病程的因素研究

B期主动脉反流(AR)的自然发展病程尚不清楚。本研究的目的旨在评估AR进展的决定因素、速率和后果。本研究纳入分析了1077名≤中度慢性AR的患者(平均年龄66 ± 15),有196名(18%)患者存在基线水平的轻度AR,465名(43%)患者存在轻-中度AR,416名(39%)患者存在中度AR,进展为中重度AR(C/D期)的10年发生率分别为12%, 30%和53%。经过平均4.1年时间的随访,有

盘点:JACC十一月第三期研究一览

1. 重复心脏磁共振对急性心梗患者预后价值研究DOI: 10.1016/j.jacc.2019.08.1061http://www.onlinejacc.org/content/74/20?current-issue=y心脏磁共振(CMR)被广泛应用在急性心梗(AM)的诊断上,CMR常会在6个月后复查一次以评估心梗的进展情况。然而,6个月CMR的临床和预后作用尚不清楚。本研究纳入分析了ITAM

AHA 2019丨COLCOT试验:COLchicine心血管结局试验

2019年11月16日,一年一度的美国心脏协会科学年会(AHA)在美国宾夕法尼亚州费城隆重启幕,来自世界各地的15000多名顶尖医生、科学家、心脏病专家、保健专业人员和其他人士参加本次会议,讨论心血管科学和医学的未来。来自加拿大蒙特利尔心脏研究所的Jean-Claude Tardif教授在第一场LBS专场中为大家揭晓了COLCOT试验的最新研究结果,COLCOT试验的结果将确定,用小剂量消炎药秋水

Eur Heart J:Alirocumab对急性冠脉综合征患者心血管预后的影响

由此可见,在新近的ACS患者中,Alirocumab可改善患者结局,且与年龄无关。这表明降低LDL-C是ACS老年患者重要的预防干预措施。